MedDataX Logo

Prognostic Factors for All Types of Cancer Combined

NCT ID: NCT00704587

Last Updated: 2016-04-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

520 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-11-30

Study Completion Date

2015-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate every possible applicability of flow cytometrical analysis in the intracellular detection of tumor-related material in activated macrophages in the broadest range of cancer types.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Could Ki-67 be Used as a Diagnostic or Prognostic Marker in Hemato-oncological Diagnostics?

NCT04517175

Myelodysplastic Syndromes Acute Myeloid Leukemia Myelodysplastic Syndrome/Neoplasm
UNKNOWN

Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or Pancreatic Cancer

NCT00898781

Breast Cancer Colorectal Cancer Ovarian Cancer +1 more
TERMINATED

Biobank Carcinoma: Storing Blood and Protein of Patients With Cancer

NCT01084785

Cancer
RECRUITING

Cancer Stem Cells in Acute Leukemia

NCT03735797

Acute Leukemia
ACTIVE_NOT_RECRUITING

A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer

NCT05708599

Non-Small-Cell Lung Carcinoma Colorectal Cancer Pancreatic Ductal Adenocarcinoma
ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* (Suspicion of) presence of cancer in the broadest sense of the word
* Must be able to understand and sign written informed consent

Exclusion Criteria

* None
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Maastricht University Medical Center

OTHER

Sponsor Role collaborator

Atrium Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dennis Japink

drs

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dennis Japink, MD

Role: PRINCIPAL_INVESTIGATOR

Atrium Medical Centre Parkstad, Heerlen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Atrium Medical Centre Parkstad

Heerlen, Limburg, Netherlands

Site Status

Maastricht University Medical Centre

Maastricht, Limburg, Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

METC 06-p-47

Identifier Type: -

Identifier Source: secondary_id

MEC 08-02-030

Identifier Type: -

Identifier Source: secondary_id

NL14215.096.06

Identifier Type: -

Identifier Source: secondary_id

ProFaCo

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cancer Stem Cell Markers and Prognostic Markers in Circulating Tumor Cells
NCT01286883 TERMINATED
Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal
NCT05530759 RECRUITING
Analysis of Circulating Tumor Markers in Blood
NCT04025541 RECRUITING NA
Prospective and Retrospective Cohort Study to Find New Prognostic Factors and Therapeutic Targets in Patients With Newly Diagnosed or Relapsed Malignant Hematologic Disorder Excluding Acute Leukemia
NCT02330718 UNKNOWN
CIRculating CANcer MAster-Protocol
NCT05089747 RECRUITING
Morehouse Total Cancer Care Protocol
NCT04804878 RECRUITING
Analysis of Circulating Tumor Markers in Blood - ALCINA 5
NCT07060950 NOT_YET_RECRUITING NA
Culture of Circulating Tumor Cells Isolated From Cancer Patients With Metastatic Disease
NCT02781025 COMPLETED
Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques
NCT07035587 RECRUITING
Study of Tissue and Blood Samples From Patients With High-Grade Glioma
NCT01004887 COMPLETED
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
NCT00685750 TERMINATED NA
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
NCT04985357 WITHDRAWN
Validation of MMS Test for Cancer Monitoring
NCT02113683 TERMINATED
Nuclear Matrix and Cancer: Proteomic and Genomic Analyses Using Microarray in Cells Obtained Via Thoracocentesis
NCT01284777 COMPLETED
Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer.
NCT00974610 COMPLETED
Circulating Tumor Cells in Solid Tumors
NCT03161821 COMPLETED
Analysis of Whole Body Magnetic Resonance Imaging and Liquid Biopsy for Early Detection of Cancer in Patients With a Strong Family History of Cancer
NCT05868486 ACTIVE_NOT_RECRUITING EARLY_PHASE1
Predicting Progression of Developing Myeloma in a High-Risk Screened Population
NCT05837884 RECRUITING NA
A Study to Explore Biomarkers in Samples of Blood, Urine, Stools, Hair Follicles and Saliva From Patients With Cancer
NCT05574738 RECRUITING
Blood Brain Barrier Differences in Patients with Brain Tumors Undergoing Surgery
NCT03071913 COMPLETED
Micro Assays for HemATology Malignancies Antibody Treatment
NCT07018310 NOT_YET_RECRUITING NA
"Principle Test" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+.
NCT05818865 ACTIVE_NOT_RECRUITING NA
Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment
NCT02105168 UNKNOWN NA
CPCT-02 Biopsy Protocol
NCT01855477 COMPLETED NA
UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer
NCT00900094 COMPLETED